Blog
RSS FeedPosted by Michael Wonder on 20 Jan 2023
UK's voluntary scheme for branded medicines, pricing and access (VPAS) faces a potential crisis
19 January 2023 - The UK has a “voluntary scheme for branded medicines, pricing, and access” or VPAS, which sets a ...
Posted by Michael Wonder on 19 Jan 2023
NICE recommends reimbursement for Translarna
19 January 2023 - Only approved treatment for the underlying cause of nonsense mutation Duchenne muscular dystrophy. ...
Posted by Michael Wonder on 19 Jan 2023
The battle over European drug pricing
19 January 2023 - UK and EU must balance health cost control with plans to grow life sciences. ...
Posted by Michael Wonder on 19 Jan 2023
NICE recommends all oral triplet regimen for patients living with relapsed or refractory multiple myeloma
19 January 2023 - Since its launch in December 2017, ixazomib has been funded through the Cancer Drugs Fund and has ...
Posted by Michael Wonder on 18 Jan 2023
Voxelotor for the treatment of patients with sickle cell disease
11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on using voxelotor ...
Posted by Michael Wonder on 18 Jan 2023
Maribavir for the treatment of patients with a refractory cytomegalovirus infection after transplant
18 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 16 Jan 2023
AbbVie and Eli Lilly, two of the world’s largest pharmaceutical companies, have sent a warning signal to the UK government by leaving the voluntary medicines pricing agreement in protest over increasingly punitive revenue clawbacks
16 January 2023 - AbbVie and Lilly have left the UK’s Voluntary Scheme for Branded Medicines Pricing and Access, a ...
Posted by Michael Wonder on 16 Jan 2023
Angiotensin II acetate for the treatment of patients with vasosuppressor-resistant hypotension caused by septic or distributive shock
16 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 11 Jan 2023
Nivolumab in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with advanced, HER2 negative gastric, gastro-oesophageal junction or oesophageal adenocarcinoma
11 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 04 Jan 2023
Mobocertinib succinate for patients with advanced EGFR exon 20 insertion mutation positive non-small-cell lung cancer after platinum-based chemotherapy
4 January 2023 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 22 Dec 2022
NICE recommends a weekly injection for treating growth failure in children
22 December 2022 - This recommendation comes from a pilot to develop simpler, faster evaluations for the appraisal of some treatments. ...
Posted by Michael Wonder on 20 Dec 2022
NICE recommends Enhertu for more people with advanced breast cancer
20 December 2022 - Hundreds more people eligible for breast cancer drug Enhertu as NICE recommends it for earlier stage ...
Posted by Michael Wonder on 15 Dec 2022
Avatrombopag maleate for the treatment of patients with primary chronic immune thrombocytopenia
15 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Esketamine hydrochloride for patients with treatment-resistant depression
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...
Posted by Michael Wonder on 15 Dec 2022
Trifluridine with tipiracil hydrochloride for the treatment of patients with metastatic gastric cancer or gastro-oesophageal junction adenocarcinoma after two or more treatments
14 December 2022 - The Department of Health and Social Care has asked NICE to produce guidance on the use of ...